Clinical Trial Update: A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction [Phase 3]

View source ↗

Summary

Phase 3 multicenter trial comparing a seven-day reduced venetoclax exposure with azacitidine to standard continuous venetoclax exposure with azacitidine in trea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Leukemia, B-Cell, Chronic, Leukemia | Phase 3 | Status: NOT_YET_RECRUITING